Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by LUCENTIS Biosimilar
BostonGene Named To The 2023 CB Insights' Digital Health 50 List
BioTechnology BostonGene’s innovative solutions and deep expertise in AI-based molecular and immune profiling recognized as a leader in diagnosis and imaging, propelling precision medicine for patients with cancer and other immune-related diseases WALTHAM, Mass.--(BUSINESS WIRE)--CB Insights named BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, to its fifth-annual Digital Health 50 showcasing the 50 most promising private digital health companies of 2023.
BioStrand Unveils A Revolutionary Approach To Biological Sequence Retrieval: A Fusion Of Natural Language Processing And Database Research
VICTORIA, British Columbia--(BUSINESS WIRE)--$IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary, BioStrand®, has published a preprint of its groundbreaking white paper titled, "New Paradigm for Biological Sequence Retrieval Inspired by Natural Language Processing and Database Research" on bioRχiv.
Tevogen Bio Introduces Tevogen.ai To Enhance Patient Accessibility And Accelerate Innovation Leveraging Artificial Intelligence
WARREN, N.J.--(BUSINESS WIRE)--#COVID19--Tevogen Bio Inc (“Tevogen Bio”) announces the inception of Tevogen.ai, a new initiative focused on harnessing the potential of artificial intelligence (AI) for the enhancement of drug discovery, development, manufacturing, distribution, and patient access.
Evozyne Announces $81 Million Financing Round To Advance Generative AI For Therapeutic Discovery And Drug Development
BioTechnology New investor OrbiMed expects platform to reduce development time for novel treatments and therapeutic approaches CHICAGO--(BUSINESS WIRE)--Evozyne announced the closing of an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. Fidelity Management & Research Company and OrbiMed led the funding with participation from NVentures, NVIDIA’s venture capital arm.
SimBioSys Partners With CancerX To Accelerate Innovation In Cancer Care
The company joins the public-private partnership efforts to drive the development and equitable deployment of innovative solutions that can reduce the burden of cancer CHICAGO--(BUSINESS WIRE)--Today, SimBioSys, the TechBio company that combines the power of Artificial Intelligence (AI), spatial biophysics, and data science to redefine precision medicine, transform patient care, and defeat cancer announces it will be one of the founding members of the CancerX initiative.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with LUCENTIS
Contact LUCENTIS, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack